Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101 Biotech Investing
Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies Biotech Investing
Shire Acquires sanaplasma AG Boosting Plasma Collection Network for Immunology Franchise Biotech Investing
Gilead and Galapagos Announce Tortuga Phase 2 Study of Filgotinib in Ankylosing Spondylitis Achieves Primary Endpoint Biotech Investing
Dermira Provides Launch Readiness Update for QBREXZA (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis Biotech Investing
Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China Biotech Investing
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial Genetics Investing
Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart in Patients With Knee Cartilage Damage Genetics Investing
Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma Biotech Investing
Tyme Exceeds Enrollment Expectations for the Phase II Trial of SM-88 in Pancreatic Cancer Biotech Investing
